Literature DB >> 8403503

Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease.

H C Reinecker1, M Steffen, T Witthoeft, I Pflueger, S Schreiber, R P MacDermott, A Raedler.   

Abstract

The perpetuation of inflammation in ulcerative colitis and Crohn's disease may be regulated in part by an increased secretion of proinflammatory cytokines due to either an appropriate response to initial stimulating agents, and/or due to an impaired down-regulation of cytokine secretion. The aim of this study was to determine the secretion patterns of the proinflammatory cytokines tumour necrosis factor-alpha (TNF-alpha), IL-6 and IL-1 beta, from isolated lamina propria mononuclear cells (LPMNC) isolated from colonic biopsies from patients with untreated ulcerative colitis or Crohn's disease. LPMNC isolated from involved inflammatory bowel disease (IBD) mucosa spontaneously produced increased amounts of TNF-alpha, and IL-6, and IL-1 beta. The TNF-alpha secretion from IBD LPMNC could be further enhanced by pokeweed mitogen stimulation. The secretion patterns of TNF-alpha and IL-1 beta by LPMNC from patients with either ulcerative colitis or Crohn's disease demonstrated a close correlation with the degree of tissue involvement and mucosal inflammation. LPMNC from non-involved ulcerative colitis mucosa secreted markedly increased levels of IL-6 compared with non-involved Crohn's disease mucosa or control mucosa. The heightened IL-6 secretion from LPMNC from non-involved ulcerative colitis mucosa without visible or microscopic signs of inflammation indicates that the pathophysiologic mechanisms involved in the initiation of inflammation may differ between ulcerative colitis and Crohn's disease. The determination of proinflammatory cytokine secretion by isolated LPMNC from colonoscopic biopsies may be a sensitive method for monitoring the severity of mucosal inflammation in IBD patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8403503      PMCID: PMC1534387          DOI: 10.1111/j.1365-2249.1993.tb05997.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  44 in total

1.  Identification of an inducible endothelial-leukocyte adhesion molecule.

Authors:  M P Bevilacqua; J S Pober; D L Mendrick; R S Cotran; M A Gimbrone
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

2.  Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1.

Authors:  R Philip; L B Epstein
Journal:  Nature       Date:  1986 Sep 4-10       Impact factor: 49.962

3.  Enhancement of the interleukin 2 receptor expression on T cells by multiple B-lymphotropic lymphokines.

Authors:  T Noma; T Mizuta; A Rosén; T Hirano; T Kishimoto; T Honjo
Journal:  Immunol Lett       Date:  1987-07       Impact factor: 3.685

4.  Tumor necrosis factor-alpha induces increased hydrogen peroxide production and Fc receptor expression, but not increased Ia antigen expression by peritoneal macrophages.

Authors:  M Hoffman; J B Weinberg
Journal:  J Leukoc Biol       Date:  1987-12       Impact factor: 4.962

5.  Scintigraphic assessment of bowel involvement and disease activity in Crohn's disease using technetium 99m-hexamethyl propylene amine oxine as leukocyte label.

Authors:  J Schölmerich; E Schmidt; C Schümichen; P Billmann; H Schmidt; W Gerok
Journal:  Gastroenterology       Date:  1988-11       Impact factor: 22.682

6.  Differences in cytokine secretion by intestinal mononuclear cells, peripheral blood monocytes and alveolar macrophages from HIV-infected patients.

Authors:  M Steffen; H C Reinecker; J Petersen; C Doehn; I Pflüger; A Voss; A Raedler
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

7.  Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1 species.

Authors:  J S Pober; L A Lapierre; A H Stolpen; T A Brock; T A Springer; W Fiers; M P Bevilacqua; D L Mendrick; M A Gimbrone
Journal:  J Immunol       Date:  1987-05-15       Impact factor: 5.422

8.  Recombinant human TNF alpha stimulates production of granulocyte colony-stimulating factor.

Authors:  H P Koeffler; J Gasson; J Ranyard; L Souza; M Shepard; R Munker
Journal:  Blood       Date:  1987-07       Impact factor: 22.113

9.  Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor.

Authors:  K Matsushima; K Morishita; T Yoshimura; S Lavu; Y Kobayashi; W Lew; E Appella; H F Kung; E J Leonard; J J Oppenheim
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

10.  Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells.

Authors:  M L Dustin; T A Springer
Journal:  J Cell Biol       Date:  1988-07       Impact factor: 10.539

View more
  268 in total

1.  Activation of signal-transducer and activator of transcription 1 (STAT1) in pouchitis.

Authors:  T Kühbacher; P Gionchetti; J Hampe; U Helwig; P Rosenstiel; M Campieri; H J Buhr; S Schreiber
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

2.  Cytokine mRNA expression in mucosal biopsies from German shepherd dogs with small intestinal enteropathies.

Authors:  A J German; C R Helps; E J Hall; M J Day
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

3.  Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease.

Authors:  E Louis; C Ribbens; A Godon; D Franchimont; D De Groote; N Hardy; J Boniver; J Belaiche; M Malaise
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

4.  Activation of nuclear factor kappaB as a target for anti-inflammatory therapy.

Authors:  S Schreiber
Journal:  Gut       Date:  1999-03       Impact factor: 23.059

5.  Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease.

Authors:  J Bauditz; S Wedel; H Lochs
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

6.  Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria.

Authors:  N Borruel; M Carol; F Casellas; M Antolín; F de Lara; E Espín; J Naval; F Guarner; J R Malagelada
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

7.  T cell activation causes diarrhea by increasing intestinal permeability and inhibiting epithelial Na+/K+-ATPase.

Authors:  Mark W Musch; Lane L Clarke; Daniel Mamah; Lara R Gawenis; Zheng Zhang; William Ellsworth; David Shalowitz; Navdha Mittal; Petros Efthimiou; Ziad Alnadjim; Steve D Hurst; Eugene B Chang; Terrence A Barrett
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

8.  Modulation of cytokine release from colonic explants by bacterial antigens in inflammatory bowel disease.

Authors:  S Dionne; S Laberge; C Deslandres; E G Seidman
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

9.  Toll-like receptor 4, F4/80 and pro-inflammatory cytokines in intestinal and mesenteric fat tissue of Crohn's disease.

Authors:  Raquel F Leal; Marciane Milanski; Maria de Lourdes S Ayrizono; Andressa Coope; Viviane S Rodrigues; Mariana Portovedo; Luiza M F Oliveira; João J Fagundes; Cláudio S R Coy; Lício A Velloso
Journal:  Int J Clin Exp Med       Date:  2013-01-26

10.  Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.

Authors:  A Di Sabatino; R Ciccocioppo; B Cinque; D Millimaggi; R Morera; L Ricevuti; M G Cifone; G R Corazza
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.